European Citizens Initiative: European Commission replies to ‘One of Us’ – Q&A
Europese Commissie, 28 mei 2014
In een lang document met vragen en antwoorden wijst de Europese Commissie het burgerinitiatief “One of Us” van de hand. Financiering van onderzoek met menselijk embryo’s gaat daardoor door.
What was the request of the ECI ‘One of Us’?
The ‘One of Us’ initiative had asked the EU to end the financing of activities which presuppose the destruction of human embryos, in particular in the areas of research, development aid and public health. The ECI requested changes to the Financial Regulation, the Horizon 2020 regulation and the Development Cooperation Instrument (DCI) regulation.
For all details on the initiative, consult the organisers’ website at http://www.oneofus.eu/
1. Research involving human Embryonic Stem Cells (hESC)
What are embryonic stem cells?
Embryonic stem cells, sometimes known as the body’s master cells, are a type of cell that possesses two unique characteristics: they can develop into any of the 200 or so cell types found in the body and, under the right conditions, they are able to multiply indefinitely to form a cell line. These characteristics indicate the potential of these cells for tissue repair after injury or disease. Human embryonic stem cells were first isolated and cultured in 1998.
Why are human embryonic stem cells used in research?
Stem cell research offers hope for serious and/or life-threatening diseases, such as Parkinson’s, which are currently untreatable and where life is at stake. Therapies based on human embryonic stem cells are already being tested in patients. The first clinical trial took place in the US for spinal cord injury repair and the first European study took place in the UK for blindness.
Some biologists also use embryonic stem cells to understand how our tissues are maintained and repaired in health, and how disease develops and might be treated. For example, research based on use of human embryonic stem cells has revealed the molecular machinery controlling development of gut and associated organs, shown how organs develop in three-dimensional culture and helped us understand the genetic control of a very serious rare disease, called fragile-X syndrome.
Where do embryonic stem cell lines come from?
All current human embryonic stem cell lines come from four to five day old blastocysts, which consist of a hollow ball of around 100 cells, left over from in vitro fertilization (IVF).
Each cycle of IVF can produce many such blastocysts, some of which are implanted into the woman, with the rest stored by freezing them. After a couple has completed their treatment, they must decide what to do with any remaining blastocysts. They can continue paying to store them or they can defrost them, which destroys them. One option is to donate the frozen blastocysts for research. Only these donated blastocyts are the source of human embryonic stem cell lines.
Do you need a new embryonic stem cell line for each research project?
No, researchers do not need to start anew for every study they carry out. Cells taken from one 4 to 5 day old blastocyst can be made to multiply in the laboratory to create a ‘cell line’ that is able to produce an almost infinite number of embryonic stem cells, all with the same genetic make-up. Many cell lines are kept in non-profit stem cell banks that can be accessed by researchers all over the world. Existing cell lines are also exchanged at no cost between laboratories in the context of research programmes, under tight legal controls.
What position do Member States take on human embryonic stem cell research?
There is a diversity of legislative provisions among Member States on human embryonic stem cell research. 18 Member States permit, subject to their oversight and conditions, research involving human embryonic stem cells, three prohibit it (PL, LT, SK) and the rest have no specific legislation1. The EU has no competence to harmonise the legal situation in Member States.
What is the policy towards the use of human embryonic stem cells in EU-funded research?
In view of the different legal situation and practices in EU Member States, the EU has since 2002 had its own clear ethical and legal framework on human embryonic stem cell research funded from the EU budget. The current framework, adopted in 2007 and which has been renewed for the duration (2014-2020) of Horizon 2020, the EU’s new research and innovation programme, consists of the so-called triple lock system.
• First and foremost, national legislation is respected – EU projects must follow the laws of the country in which research is carried out;
• In addition, all projects must be scientifically validated by peer review and must undergo rigorous ethical review;
• Finally, EU funds may not be used for derivation of new stem cell lines, or for research that destroys embryos (blastocysts) – including for the procurement of stem cells.
Since one of the principles of EU research is that it operates on a bottom-up basis, the European Commission does not publish calls for proposals specifically for research using human embryonic stem cells. It is for the scientists to propose the methods and materials they need for a particular study. EU research allows for the comparison of different cell types. One of the challenges for research is to find the best cell source for a particular application.
How do you enforce these rules?
All projects involving stem cells go through an ethics review undertaken by independent experts who review proposals for conformity with all the relevant clauses in the Horizon 2020 legislation.
Reporting requirements are set out in the grant agreements and running projects are monitored by the Commission. Any revisions needing authorisation are referred to the Member States.
The ethical panel can recommend a mandatory ethical review be carried out during the course of a project if necessary. Requirements put forward by the review become project contractual obligations. The procedures for the review are based on Opinion 22 of the European Group on Ethics in Science and New Technologies2.
How much has the EU spent on human embryonic stem cell research?
Since 2007, the EU has funded 27 collaborative health research projects involving the use of human embryonic stem cells with an EU contribution of about €157 million. Human embryonic stem cell research projects represent approximately one third of health projects on all forms of stem cells.
In addition, the European Research Council has funded 10 projects for an EU financial contribution of about €19 million and there have been 24 Marie Skłodowska-Curie actions involving human embryonic stem cell research worth €23 million.
Are there alternatives to embryonic stem cells?
Embryonic stem cells possess certain properties and carry out certain functions that cannot currently be obtained from other cell types.
Induced pluripotent stem cells, whose discoverers were awarded the 2012 Nobel Prize, have many similar properties to embryonic stem cells. They are of most use in drug development, for instance to screen potential new medicines. If they could be produced to clinical standard, which they are not at present, they might be developed for therapeutic purposes in the future. In recent years the number of scientific publications on human embryonic stem cells has held steady, suggesting that this area of research is still active despite the development of induced pluripotent stem cells. Without prior research on human embryonic stem cells, induced pluripotent stem cells would not have been developed.
There are various types of “tissue-specific” or “adult” stem cells; while these cells are useful in specific cases, they are limited in their potential and largely make the cell types found in the tissue from which they are isolated.
What is the EU doing to promote/develop alternatives?
The 27 research projects involving human embryonic stem cells mentioned above represent about a third of the 87 projects in the FP7 health programme on all sources of stem cells; these include haematopoietic, mesenchymal, tissue-derived or adult stem cells and induced pluripotent stem cells. Nearly all of the recent human embryonic stem cell projects also include complementary work on human induced pluripotent stem cells. During the course of FP7 new stem cell sources were developed, and others rejected. The EU approach to stem cell research is to let science decide the best cell source for a particular application, while respecting the safeguards in place.
Where can I get information about EU stem cell research projects?
EU projects set up their own websites. These provide information about their work to other scientists, patients interested in possible treatments and the public in general. Centralised information on all EU research projects is available here: http://cordis.europa.eu/home_en.html
In addition, the EU supports Eurostemcell (www.eurostemcell.org), “Europe’s stem cell hub”, is a multi-lingual website providing reliable, independent information and road-tested educational resources on stem cells and their impact on society.
Does the Innovative Medicines Initiative support human embryonic stem cell research and does it follow the same ethical and supervisory rules and procedures as Horizon 2020?
So far the Innovative Medicines Initiative has not supported embryonic stem cell research. In principle, it could do so, in which case it would have to follow the Horizon 2020 rules and procedures.
Doesn’t the Court of Justice’s “Brüstle” judgement prohibit hESC research and its funding?
The so-called Brüstle judgement of the European Court of Justice (Case C-34/10) was referred to by the organisers when presenting their case. However, the Court noted in that ruling which concerned the Biotech Directive (98/44/EC), that the purpose of the European legislation in question is not to regulate the use of human embryos in the context of scientific research; the ruling was limited to the patentability of biotechnological inventions and did not deal with the question of whether such research can be carried out and whether it can be funded.
Why does the EU still fund such research if, after the Brüstle judgement, its results cannot be patented?
The EU funds hESC research first and foremost because of its societal benefits, namely because such research has great therapeutic potential with respect to a wide range of life-threatening diseases. The use of the results of EU-funded hESC research is not limited to their patenting. Usage can take the form, for instance, of follow-up research or clinical use.
Does the Commission fund, through H2020, patent applications made outside the EU, even if they contravene the Brüstle verdict?
No. Such costs are not eligible for funding under Horizon 2020.